Andoh M, Gemma A, Takenaka K, Hisakatsu S, Yamada K, Usuki J, Hasegawa K, Sakonji M, Kudoh S, Tsuboi E
Fourth Department of Internal Medicine, Nippon Medical School, Tokyo.
Intern Med. 1994 May;33(5):271-6. doi: 10.2169/internalmedicine.33.271.
In 93 patients with inoperable non-small cell lung carcinoma who underwent chemotherapy including cisplatin, the prognostic value of 9 factors were determined using Cox's proportional hazard model. Univariate analysis revealed that patients with a performance status of grade 2 (p < 0.01) or 3 (p < 0.05), those with stage IV disease (p < 0.05), those with a serum neuron specific enolase (NSE) level > 7.0 ng/ml (p < 0.001), and those with a low serum albumin level (p < 0.05) had a significantly worse prognosis. Multivariate analysis showed that a performance status of 2 or 3 and a high NSE serum level were associated with a significantly worse prognosis. More attention should be paid to the serum NSE level in patients with non-small cell lung carcinoma, because it not only reflects the tumor volume, but is also a prognostic factor which is dependent on individual tumor characteristics.
在93例接受包括顺铂在内化疗的不可切除非小细胞肺癌患者中，使用Cox比例风险模型确定了9个因素的预后价值。单因素分析显示，体能状态为2级（p<0.01）或3级（p<0.05）的患者、IV期疾病患者（p<0.05）、血清神经元特异性烯醇化酶（NSE）水平>7.0 ng/ml的患者（p<0.001）以及血清白蛋白水平低的患者（p<0.05）预后明显较差。多因素分析表明，体能状态为2级或3级以及NSE血清水平高与预后明显较差相关。对于非小细胞肺癌患者应更多关注血清NSE水平，因为它不仅反映肿瘤体积，也是一个依赖于个体肿瘤特征的预后因素。
